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A B S T R A C T
Purpose: The aim of this survey was to review and compare the current approaches to epilepsy
management in Central and Eastern EU (CEEU) countries.
Method: The questionnaire was sent to ten invited experts from Bulgaria, Czech Republic, Estonia,
Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. It focused on the treatment of
adults.
Results: The number of neurologists and epilepsy reference centers is highly variable in CEEU countries.
None of the analyzed states has a formal specialization in epileptology. No universal state-approved
criteria for reference centers exist in Czech Republic, Estonia, Hungary, Latvia, and Slovenia. Generally,
the protocols for epilepsy treatment in CEEU countries, including drug-resistant epilepsy, are in
accordance with international guidelines; however, most countries have their own national standards of
care and some have local clinical guidelines. Also, the reimbursement systems for antiepileptic drugs in
CEEU countries are highly variable. Seven countries have epilepsy surgery centers. The costs of epilepsy
surgeries are fully reimbursed, procedures performed abroad may also be covered. The length of time
spent on waiting lists for surgery following the completion of preoperative investigations varies from
two weeks to three years. The fraction of patients who qualiﬁed and were operated on within 12 months
ranges from 20% to 100%.
Conclusion: The lack of uniﬁed procedures pertaining to the evaluation and therapy of epilepsy is
reﬂected by marked differences in access to treatment modalities for patients from CEEU countries.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The number of people with epilepsy is estimated to be
approximately 50 million worldwide, amongst which 20–40%
are drug-resistant.1–3 Similarly to other chronic disorders, the
management of epilepsy constitutes a signiﬁcant ﬁnancial burden
for healthcare systems. The central role of pharmacotherapy makes
the cooperation between specialized healthcare providers andvier Ltd. All rights reserved.
Fig. 1. Questionnaire on the management of epilepsy in adult patients.
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optimal delivery of care.
It is believed that the socioeconomic changes that took place
in Central and Eastern European countries over the last two
decades, including accession to the European Union (EU), have
had highly variable effects on access to care for people with
epilepsy; however, there is a lack of relevant data. The aim of
this survey was to review and compare current approaches to
epilepsy management in Central and Eastern EU (CEEU)
countries.
2. Methods
The data presented in this paper was gathered from the Central
Europe Epilepsy Experts Working Group. In 2010, all respective
experts in the ﬁeld of epileptology were invited to participate in
this body, including representatives of ILAE chapters and
reference centers. In March 2012, the questionnaire developed
by the Group’s Steering Committee (Fig. 1) was sent to ten experts
from Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania,
Poland, Romania, Slovakia, and Slovenia who had responded to the
invitation. The survey questions focused on the characteristics of
the healthcare system, diagnostic process for epilepsy and patientﬂow, treatment options and other health services available for
patients with epilepsy, pharmacoeconomics of epilepsy, as well as
on country-speciﬁc issues relating to epilepsy management in
CEEU states. The availability of epilepsy reference centers was
analyzed on the basis of the state-approved criteria of participat-
ing countries (if any) and in relation to the International League
Against Epilepsy (ILAE) criteria (i.e. availability of at least two
neurologists/epileptologists, 24-h availability of video-EEG,
availability of neuroimaging – MRI, and availability of a
neuropsychologist).
The participating specialists were asked to complete the survey
based on validated sources of information, e.g. literature databases,
ministerial registries, registries run by local medical councils, etc.
The outcome of the survey was summarized in the form of an initial
report, which constituted the basis for this paper.
3. Results
3.1. Healthcare systems of CEEU member countries
CEEU member countries’ health care systems are mainly
ﬁnanced by all citizens, who make compulsory health insurance
contributions. The differences between particular countries
Table 1
Availability of specialist resources in Central and Eastern EU countries.
Country Certiﬁed neurologists State-licensed reference centers Reference centers (ILAE criteria) Patient organizations (n)
N Per 100,000 n Population covered n Population covered
Bulgaria 900 12.3 11 663,636 6 1,216,666 1
Czech Republic 1097 10.4 n/a n/a 6 1,750,000 2
Estonia 152 11.3 n/a n/a 2 670,170 1
Hungary 1310 13.1 n/a n/a 4 2,500,000 7
Latvia 288 14.4 n/a n/a 0 n/a 1
Lithuania 357 11.0 2 1,622,300 1 3,244,601 2
Poland 3930 10.3 10 3,800,000 2 19,000,000 11
Romania 1000 4.8 4 5,250,000 2 10,500,000 2
Slovakia 586 10.6 6 921,666 6 921,666 2
Slovenia 86 4.2 n/a n/a 1 2,050,000 3
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centralized organization (national health or sickness fund) with
regional branches. However, in some countries, e.g. Czech Republic
and Slovakia, patients can choose amongst several insurance
providers. In this case, the insurer sets the rules and limits for
ﬁnancing healthcare service in agreement with the local health
ministry.
3.2. Availability of specialist care
In all analyzed countries, the care of patients with epilepsy falls
into the domain of neurology. However, the number of physicians
specializing in neurology is highly variable. This variability is
reﬂected by the number of specialists per 100,000 of the
population, ranging from 4.2/100,000 in Slovenia to 14.4/
100,000 in Latvia (see Table 1 for more detail).
None of the analyzed countries has a formal specialization in
epileptology; however, unofﬁcial titles of epilepsy specialists are
issued by scientiﬁc societies in the Czech Republic, Hungary and
Poland. The Czech Republic is the only country that provides
recognized epilepsy experts with additional entitlements (higher
limits for antiepileptic drug prescriptions). In all CEEU countries,
epileptology is included in neurology training curricula. The
courses are organized and certiﬁed by various organizations:
medical universities, scientiﬁc and professional societies, and
specialized units dedicated to postgraduate training and special-
ized training of physicians.
There is also a great variability of the number of epilepsy
reference centers available in particular countries. Expressed per
number of inhabitants, the most state-licensed reference centers
are available in Bulgaria and the fewest in Poland and Romania.
Noticeably, no universal state-approved criteria exist for
reference centers in the Czech Republic, Estonia, Hungary,
Latvia, and Slovenia; consequently, centers located in these
countries range from specialized epilepsy surgery centers to
academic neurology clinics and privately owned clinics. If
universal ILAE criteria are applied, the relative availability of
reference centers is greatest in Estonia and Slovakia and the
lowest in Poland and Romania. No centers fulﬁll the ILAE criteria
in Latvia (see Table 1).
3.3. Patient organizations
Epilepsy patients’ organizations are registered in all CEEU
countries. Their numbers vary from one to more than ten (Table 1).
The role of these organizations is limited to the individual support
of patients rather than to system-oriented activities in most
countries. However, patient organizations are involved in the
development of reimbursement policies for antiepileptic agents in
Bulgaria, the Czech Republic, Estonia, Romania, Slovakia, and
Slovenia.3.4. Organization of diagnostic and therapeutic process
Neurologists are at the center of the diagnostic and therapeutic
processes for patients with epilepsy. General practitioners play a
supportive role, while complicated cases are typically seen in
reference centers (if available).
In most CEEU countries, emergency medicine specialists
constitute the initial point of contact in the diagnostic process
of epilepsy. If this disorder is suspected based on the reported
symptoms, the patient is referred to a neurologist, who conﬁrms
diagnosis and provides treatment. Usually, the general practitioner
assumes direct charge of the patient’s treatment subsequently,
with neurological follow-up visits every 6 months. However, the
optimal cooperation between neurologists and general practi-
tioners is a problem in many countries. Furthermore, the local
factors lead to some deviations from typical diagnostic and
therapeutic processes. For instance, approximately 20% of epilepsy
patients in Latvia are treated by psychiatrists due to the markedly
shorter waiting time for a psychiatric consultation.
Typically, it is recommended that the highest-ranked reference
center should be involved in cases involving particular diagnostic
and/or therapeutic challenges, but the criteria for such cases are
not clearly deﬁned in most countries. Theoretically, similarly to
other EU countries, drug-resistant epilepsy should be one of the
domains of the highest-ranked reference centers. The most
frequently applied criterion for drug resistance is the failure of
at least two appropriately chosen and well-tolerated antiepileptic
drugs in monotherapy, usually within a deﬁned period of time.
However, many physicians do not adhere to this criterion as it is
not been ofﬁcially adopted. In most cases, this leads to the marked
overloading of reference centers with less complicated cases,
which limits their capacity to see patients with truly drug-resistant
epilepsy. The only exception is Bulgaria, where only a reference
center is allowed to conﬁrm diagnosis of drug-resistant epilepsy
and can provide access to fully reimbursed antiepileptic drug
treatment (including treatment involving newer antiepileptic
agents).
3.5. Therapeutic possibilities and pharmacoeconomics
Generally, the protocols for epilepsy treatment in CEEU
countries, including for drug-resistant epilepsy, are consistent
with ILAE guidelines. However, most countries have their own
national standards of care and, in some areas, local clinical
guidelines are used. These standards are usually determined by the
possibilities of reimbursement for pharmacotherapy in a given
country. In some cases, new generation drugs can be reimbursed as
the ﬁrst-line treatment (Table 2).
In most countries, seizure control or reduction is the basic
criterion of treatment effectiveness. Ofﬁcially, the monitoring of
adverse effects of antiepileptic agents is obligatory in all analyzed
Table 2
Reimbursement systems of pharmacotherapy in Central and Eastern EU countries.
Country Full/partial reimbursement Reimbursed in drug-resistant
epilepsy only/special indications
No reimbursement
Bulgaria CBZ, CZP, ESM, GBP, LEV, LTG, OXC, PGB, PHT, TGB, TPM, VPA LCM, RGB
Czech Republic CBZ, CLB, CZP, DZP, ESLa, ESM, GBP, LCMa, LEV, LTG, PB, PGB, PHT, PRM,
RGBa, RFNa,SLT, TGB,
TPM, VGB, VPA, ZNS
Estonia CBZ, LEV, LTGb, OXCb, PB, PHT, PRM, TPMb, VPA LEV, RGB
Hungary CBZ, CLB, CZP, FBM, GBP, LCM, LEV, LTG, OXC, PB, PHT, PRM, RFN, RGB,
TPM, VGB, VPA, ZNS
FBMa, RFNa, TPMa ESM, MSX, SLT
Latvia CBZc, CZPc, DZPc, GBPd, LEVe, LTGc, OXCd, PGBe, RGBe, TPMd, VPAc GBPd, LEVe, OXCd, PGBe, RGBe, TPMd
Lithuania CBZ, CZP, DZP, ESM, GBP, LTG, OXC, NZP, PGB, PHT,
PRM, SLT, TGB, TPM, VPA
GBP, LEV, LTG, OXC, PGB, RGB, TGB, TPM CLB, ESL, FBM, LCM,
PB, RFN, VGB, ZNS
Poland CBZ, CZP, DZP, ESM, PB, PHT, PRM, VPA FBM, GBP, LEV, LTG, OXC,
RFN, TGB, TPM, VGB
CLB, ESL, LCM, PGB,
RGB, ZNS
Romania CBZ, CZP, ESM, LEV, LTG, OXC, PB, PGB, PHT, TPM, VPA LCM, RGB
Slovakia CBZ, GBP, LCM, LEV, LTG, OXC, PB, PGB, PHT, RFN, RGB, SLT, TPM,
VGB, VPA, ZNS
Slovenia CBZ, CLB, CZP, DZP, ESM, LEV, LTG, MDZ, OXC, PB, PGB, PHT,
PRM, TPM, VPA
LCMf, RGBf, STPg ESL, FBM, MSX, SLT, ZNS
a Prescription/indication limitation.
b If older AEDs are contraindicated, ineffective, or cause intolerable side effects.
c First-line treatment.
d Second-line treatment in cases resistant to CBZ, LTG, VPA.
e Prescribed after consulting a specialist in the third-line treatment of drug-resistant cases.
f If CBZ, OXC, LTG, VPA are contraindicated, ineffective, or cause intolerable side effects.
g If CLB and VPA are ineffective alone.
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any prescribed practical activities other than the recording of
adverse effects in medical documentation.
The reimbursement systems for antiepileptic drugs in CEEU
countries are highly variable. In some countries, most or all
licensed antiepileptic agents are fully reimbursed: Bulgaria, the
Czech Republic, Estonia, Latvia and Slovenia. In others, several
drugs are fully reimbursed, while the patient is responsible for the
remaining cost, in part or in full (Table 2). Various reimbursement
restrictions exist in most countries, including restrictions based on
patient’s age, seizure type, and the type, brand, and dosage of a
particular medication. In Poland, adjunctive treatment with the so-
called ‘‘new generation drugs’’ (Table 2) is only reimbursed in
patients with drug resistant epilepsy.
The healthcare systems in many countries force physicians to
prescribe generic drugs. In all CEEU countries, with the exception
of Poland and Slovakia, the reimbursement of generics constitutes
the reference price covered by the insurer.
3.6. Availability of epilepsy surgery
The following seven countries have epilepsy surgery centers:
Bulgaria, the Czech Republic, Estonia, Hungary, Lithuania, Poland
and Romania (Table 3). In all the countries mentioned, theseTable 3
Availability of epilepsy surgery procedures in Central and Eastern EU countries (2010–
Country Surgeries (per million
inhabitants/year)
Surgical centers (n) 
Bulgaria 2.74 1 
Czech Republic 7.60 4 
Estonia 7.46 1 
Hungary 3.00 3 
Latvia 4.00–6.00a 0 
Lithuania 3.11 1 
Poland 1.32 3 
Romania 0.95 1 
Slovakia 1.81–2.71a 0 
Slovenia 4.00–6.00a 0 
aAll surgeries performed abroad.centers offer their own pre-operative diagnostics. The length of
time spent on the waiting-list for surgery, following the comple-
tion of preoperative investigations, varies from two weeks to three
years. The proportion of patients found suitable for surgery and
operated within 12 months can range from 20% to 100%. The costs
of epilepsy surgery are fully reimbursed in all countries;
procedures performed abroad may also be covered by the
healthcare systems of Bulgaria, Slovakia and Slovenia. In most
CEEU countries access to vagus nerve stimulation or dietary
epilepsy treatments is limited.
4. Discussion
Our study reveals that the availability of epileptologists and
specialized reference centers varies greatly between different
CEEU countries. There are signiﬁcant provision shortfalls in some
areas. However, in view of the lack of reliable epidemiological data,
representing one of the major problems in the region, it is difﬁcult
to be certain of speciﬁc deﬁciencies. The few epidemiologic studies
available are limited for the most part by the selection of particular
populations or by being out of date.4,5 Therefore, in most cases, the
national health insurer is the principal source of data concerning
the prevalence of epilepsy. In some countries, these data are not
available to healthcare providers and scientiﬁc societies. Slovakia2011 status).
Centers with pre-operative
diagnostics (n)
Time between qualiﬁcation
and surgery
1 4 weeks
4 4–12 weeks
1 4–8 weeks
3 4–8 weeks
0 –
1 2–3 weeks
1 4–12 weeks
2 1 month–2 years
0 8–24 weeks
1 2–3 years
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epilepsy. This system is far from perfect, however, as suggested by
marked discrepancies between the number of cases registered and
the statistics provided by national insurers. Latvia is at the other
extreme, lacking any documented data on the epidemiology of
epilepsy. Consequently, the prevalence of this disease in Latvia can
only be estimated based on the statistics from the surrounding
countries.
Estimating the prevalence of drug-resistant epilepsy is even
more problematic. In the majority of the studied countries, it is
assumed not to exceed 30% of all cases. However, these are only
rough estimates based on imperfect systems of data collection.
Drug-resistant cases cannot be identiﬁed on the basis of data
provided by insurers as evidence of polytherapy is considered a
criterion for the deﬁnition of drug resistant epilepsy in some
countries. This approach can lead to an underestimation of the
prevalence of drug resistant epilepsy. In contrast, medication use
data (but not allowing for patients using polytherapy) can lead to
an overestimation of the total prevalence of epilepsy.6
When looking at drug consumption, one should keep in mind
that some patients do not take prescribed medications for a variety
of reasons. Estimating the prevalence of drug-resistant epilepsy
based on drug consumption rates is also an imperfect approach as
some antiepileptic agents are prescribed for other indications, such
as other neurologic conditions or psychiatric disorders. Further-
more, other factors related to local traditions can inﬂuence
prescription patterns of antiepileptic agents irrespective of
insurers’ policies.7,8 Finally, the insurer’s statistics are difﬁcult to
obtain. Administrative red tape or the decentralization of
healthcare systems, such as in the Czech Republic, further
complicates the process. Regardless of the accessibility of insurer’s
prevalence data, these types of data can also be confounded by
reporting bias. For instance, Hungary cases registered as having
‘‘epilepsy’’ by the national insurer include patients who have
experienced alcohol withdrawal seizures.
Another obstacle identiﬁed by this study is the lack of uniﬁed
procedures for the diagnostic and therapeutic management of
epilepsy, including drug-resistant cases. This is reﬂected by
marked differences in access to modern treatment modalities
for patients from some CEEU countries. Due to the lack of
standardization of diagnostic and therapeutic procedures, the
estimation of costs associated with the management of refractory
epilepsy in CEEU countries is virtually impossible. A marked
difference in the costs of epilepsy management within one country
was conﬁrmed by the results of a Polish multicenter study. This
study also revealed that medications and social services generate
most of the costs associated with epilepsy treatment, and that
diagnostic procedures account for less than 5% of costs spent by
healthcare system on the management of this disease.9
On the basis of these observations, ﬁnding a regional consensus
for diagnosing and treating epilepsy seems the next logical step.
Such guidelines, similar to the standards approved in other EU
states,10 could be presented to local health ministries, serving as aplatform for medical and administrative cooperation oriented
toward the optimization of care for patients with epilepsy.
However, the coordination of these activities requires deﬁned
criteria and reference center expertise. By design, such centers
should control the care of patients and play an important role in
the allocation of healthcare resources. Furthermore, they would be
responsible for the coordination of cooperation within the region.
This study constitutes a unique presentation of previously
unpublished data and experience of experts dealing with the
management of epilepsy in CEEU countries. Although the 2003
survey on the provision of epilepsy care across Europe, performed
by the ILAE Commission of European Affairs: Subcommission on
European Guidelines, included most CEEU countries participating
in our study, the ﬁndings were reported collectively and the
speciﬁc problems of Central and Eastern Europe were not
addressed separately.10 We hope that, aside from providing
information about the status of epilepsy care in CEEU countries,
our publication will stimulate speciﬁc organizational activities,
which in turn will be supported by the expert knowledge and
experience of our colleagues from Western EU centers.
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